Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dry Eye Syndrome Clear all
Completed Phase 2Phase 3 Interventional

Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome

NCT00198536
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Ecabet 2.83%, Ecabet 3.70%, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
3
States / cities
Lewiston, Maine • Andover, Massachusetts • Dover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 21, 2026, 7:03 AM EDT
Completed Not applicable Interventional

Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD

NCT02621593
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
M22-IPL
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Beverly Hills, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 21, 2026, 7:03 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD

NCT06064071
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye Disease
Interventions
Nordlys SWT IPL, Meibomian Gland Expression (MGX), Sham Nordlys SWT IPL
Device · Procedure
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Miami, Florida • Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 21, 2026, 7:03 AM EDT
Completed Not applicable Interventional Results available

TearCare System to Treat Dry Eye Disease

NCT03857919
View directory record Official record
Conditions
Dry Eye, Meibomian Gland Dysfunction
Interventions
TearCare, LipiFlow
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Scottsdale, Arizona • Laguna Hills, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 21, 2026, 7:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ocular Surface Microbiome

NCT02298881
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 21, 2026, 7:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye

NCT02420730
View directory record Official record
Conditions
Healthy Volunteers, Dry Eye Syndromes
Interventions
AGN-232411, AGN-232411 Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Artesia, California • Glendale, California • Montebello, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 21, 2026, 7:03 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

BL-RX01-TFSTAB-1402

NCT07790211
View directory record Official record
Conditions
Dry Eye
Interventions
Determine the ability of the iTrace™, BOSA™, OPD-Scan III, and IDRA to detect tear film stability utilizing Miebo®
Drug
Lead sponsor
Vance Thompson Vision
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 21, 2026, 7:03 AM EDT
Completed Phase 1 Interventional

Study of ST266 Eye Drops in Treating Dry Eye

NCT02369861
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
ST266, Refresh Lubricant Eye Drops
Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 21, 2026, 7:03 AM EDT
Recruiting Phase 4 Interventional

Single-Arm Study of a Treatment for Dry Eye in People Who Struggle to Wear Contact Lenses

NCT07510620
View directory record Official record
Conditions
Dry Eye
Interventions
Lacrifill
Drug
Lead sponsor
Vision Innovation Centers of Pennsylvania, LLC d/b/a Eye Care Specialists
Other
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kingston, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 21, 2026, 7:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tear Film Stability After Instillation of Over-the-Counter (OTC) Artificial Drops

NCT00610480
View directory record Official record
Conditions
Dry Eye Disease
Interventions
1st visit Optive, then 2nd visit Systane, 1st visit Systane, then 2nd visit Optive
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 21, 2026, 7:03 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Sjogrens Syndrome Measured by Ultrasound

NCT03411850
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Orencia, Placebo
Biological · Other
Lead sponsor
Arthritis & Rheumatism Associates, P.C.
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 21, 2026, 7:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points

NCT00345241
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Systane Ocular Drops (OTC), Placebo - Saline Drops
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 88 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2008 · Synced Oct 21, 2026, 7:03 AM EDT
Completed Phase 2 Interventional

Etanercept Therapy for Sjogren's Syndrome

NCT00001954
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Etanercept
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 7:03 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)

NCT05133180
View directory record Official record
Conditions
Dry Eye
Interventions
Oxervate, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Glendale, California • Newport Beach, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 21, 2026, 7:03 AM EDT
Terminated Phase 3 Interventional Results available

Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye

NCT02965846
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
AGN-195263, Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Artesia, California • Glendale, California • Chesterfield, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 21, 2026, 7:03 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

NCT05119920
View directory record Official record
Conditions
Dry Eye Disease, Kerato Conjunctivitis Sicca
Interventions
Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3, Placebo Ophthalmic Topical Cream
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
19
States / cities
Chandler, Arizona • Sun City, Arizona • Glendale, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 21, 2026, 7:03 AM EDT
Completed Phase 3 Interventional Results available

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3

NCT03937882
View directory record Official record
Conditions
Dry Eye Syndromes, Dry Eye
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 21, 2026, 7:03 AM EDT
Completed Not applicable Interventional Results available

Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery

NCT01808560
View directory record Official record
Conditions
Blepharitis, Dry Eye Syndrome
Interventions
LipiFlow Pre-Treatment, LipiFlow Post-treatment
Device
Lead sponsor
TearScience, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
Hoffman Estates, Illinois • Lake Villa, Illinois • Winchester, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 21, 2026, 7:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study

NCT04669561
View directory record Official record
Conditions
Dry Eye
Interventions
Lifitegrast 5% Ophthalmic Solution
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Laguna Hills, California • Jacksonville, Florida • Brecksville, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 21, 2026, 7:03 AM EDT
Completed Phase 1 Interventional

A Multi-Center Study Subjects With Dry Eye Syndrome

NCT01745887
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
EBI-005-2
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Artesia, California • Ranchero Cordova, California • Torrence, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Oct 21, 2026, 7:03 AM EDT
Completed Phase 3 Interventional Results available

Study of SkQ1 as Treatment for Dry-eye Syndrome

NCT03764735
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle)
Drug
Lead sponsor
Mitotech, SA
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Newport Beach, California • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 21, 2026, 7:03 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Single Lipiflow Treatment to Reduce Pharmacologic Burden in DED

NCT06542276
View directory record Official record
Conditions
MGD-Meibomian Gland Dysfunction
Interventions
Thermal Vectored Pulsation
Device
Lead sponsor
Dunes Eye Consultants
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dakota Dunes, South Dakota
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 21, 2026, 7:03 AM EDT
Active, not recruiting Phase 4 Interventional

A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

NCT06565650
View directory record Official record
Conditions
Dry Eye
Interventions
Miebo, Saline
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Glendale, California • Murrieta, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 21, 2026, 7:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

TrueTear in Sjogren's Disease Patients

NCT03719885
View directory record Official record
Conditions
Dry Eye Syndromes, Sjogren's Syndrome
Interventions
TrueTear Intranasal Tear Neurostimulator
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
22 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 21, 2026, 7:03 AM EDT